| Identification | Back Directory | [Name]
AKR-501 | [CAS]
570406-98-3 | [Synonyms]
YM477
E 5501
AKR-501
AS 1670542
AVATROMBOPAG
AKR-501 USP/EP/BP
Crenolanib Besylate
Avatrombopag (AKR-501)
Avatrombopag(AS1670542)
Avatrombopag Base,Avatrombopag
AKR-501; YM477; E5501; AS 1670542
1-[3-Chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbo
1-[3-Chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl]-2-pyridyl]piperidine-4-carboxylic acid
1-(3-Chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-1,3-thiazol-2-yl]carbamoyl}-2-pyridinyl)-4-piperidinecarboxylic acid
1-[3-Chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]-4-piperidinecarboxylic acid
4-Piperidinecarboxylic acid, 1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]- | [EINECS(EC#)]
1312995-182-4 | [Molecular Formula]
C29H34Cl2N6O3S2 | [MDL Number]
MFCD18633249 | [MOL File]
570406-98-3.mol | [Molecular Weight]
649.65 |
| Chemical Properties | Back Directory | [density ]
1.440 | [solubility ]
DMSO:27.33(Max Conc. mg/mL);42.07(Max Conc. mM) | [form ]
A crystalline solid | [pka]
3.04±0.70(Predicted) | [color ]
White to off-white | [InChIKey]
OFZJKCQENFPZBH-UHFFFAOYSA-N | [SMILES]
N1(C2=NC=C(C(NC3=NC(C4SC=C(Cl)C=4)=C(N4CCN(C5CCCCC5)CC4)S3)=O)C=C2Cl)CCC(C(O)=O)CC1 |
| Hazard Information | Back Directory | [Description]
Avatrombopag is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure.It was the third thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia and the first approved to treat periprocedural thrombocytopenia in patients with chronic liver disease (thereby providing an alternative to blood transfusions for these patients). Avatrombopag was approved for medical use in the United States in 2018, and in the European Union in 2019. | [Uses]
Avatrombopag is used to treat thrombocytopenia (a low number of platelets [type of blood cell needed for blood clotting]) in people with chronic (ongoing) liver disease. It is also used to treat thrombocytopenia in people with chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood).
| [Mechanism of action]
Avatrombopag is in a class of medications called thrombopoietin (TPO) receptor agonists. It works by causing the body to produce more platelets. | [target]
TPO receptor | [IC 50]
IC 50 value is 3.3 nM.
|
|
|